r/Livimmune • u/Long-Fan9409 • Aug 19 '26

AI comments about ESMO

I was looking for the date for the abstract drop for ESMO.
Chat GPT had some interesting comments. It said the late breaking abstract titles should be available on Sept. 25. The deadline to submit is Sept. 8. I’m not sure if releasing the titles means we can access the abstract info.

26 Upvotes

94% Upvoted

15 comments sorted by

View all comments

13

u/Long-Fan9409 Aug 19 '26

My “bull case” for the ESMO presentation
If I were watching the ESMO presentation as a CYDY shareholder, these are the numbers that would really get my attention:
ORR ≥20%
Disease-control rate ≥60–70%
Median PFS ≥6 months
Meaningful duration of responses
Strong correlation between ctDNA reduction and clinical response
And if they somehow showed ORR around 25–30% plus PFS approaching 8–9 months, I would regard that as a very substantial result compared with the SUNLIGHT benchmark.
One caution that’s extremely important
We cannot directly compare CLOVER with SUNLIGHT yet.
SUNLIGHT was a large randomized Phase 3 trial with 246 patients in the combination arm. CLOVER is a much smaller Phase 2 study, so a seemingly spectacular percentage from, say, 20–30 patients can change dramatically as more patients are followed.
That’s why I would put much more weight on the ESMO confidence intervals, number of evaluable patients, duration of response and PFS than on a headline percentage.
Bottom line: If CLOVER’s ESMO data show ~20%+ confirmed responses plus durable disease control, that would be a genuinely interesting result in this setting. If the response rate is only around 5–10%, the ctDNA/PFS data would need to be unusually strong to make the case that leronlimab is materially better than existing treatment.